Jamieson Bondarenko, a Director, acquired 22,000 Common Shares on a direct ownership basis at a price of $5.351USD on December 20th, 2022. This represents a $160,337 investment into the company's shares and an account share holdings change of 18.4%.
BriaCell Therapeutics is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.
BriaCell Therapeutics Corp. is an immuno-oncology biotechnology company. The Company is focused on developing treatments that boost the ability of the body's own cancer-fighting cells to destroy cancerous tumors. Its lead drug candidate, Bria-IMT, is a targeted immunotherapy being developed for the treatment of advanced breast cancer. The Company is focused on conducting Phase I/IIa clinical trial of Bria-IMT in a combination study with immune checkpoint inhibitors such as the Incyte drugs retifanlimab, an anti-PD-1 antibody like pembrolizumab, and epacadostat. Bria-IMT is a genetically engineered human breast cancer cell line with features of immune cells and clinically applied as a targeted immunotherapy. The Company is also focused on development of Bria-OTS, which is an off-the-shelf personalized immunotherapy for breast cancer, and similar immunotherapy cell lines for other cancer indications. The Bria-OTS immunotherapy is based on a patient's HLA-type.
No Comments